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ABSTRACT 
Objective: The main objective of the research work is to develop and validate a rapid UHPLC method for the estimation of assay and its related 
substances of Trichostatin A (TSA) in pharmaceutical samples. 
Methods: The UHPLC method developed for chromatographic separation between TSA and its related compounds on Poroshell 120 SB C18(50×4.6) 
mm; 2.7 µm RRLC column using Agilent RRLC (UHPLC) system with linear gradient elution. 
Results: The developed UHPLC method has shown excellent chromatographic separation between TSA and its related compounds within 12 min 
run time, during validation experiments, specificity study revealed that the peak threshold was more than the peak purity and no purity flag was 
observed. Repeatability, intra, and inter-day precision results were well within the tolerable limits. Limits of detection concentrations were found 
between 0.075 to 0.077 ppm and the limit of quantitation is between 0.252 to 0.258 ppm for related compounds and TSA. The related substances 
method recoveries were found between 80 and 120 % and assay method recovery was found between 98.0 to 102.0%.  
Conclusion: The developed method capability was proven for the assay of TSA and its related compounds in pharmaceutical samples and the 
method shows eco-friendlier than routine, conventional HPLC methods in terms of analysis time, cost and HPLC effluent waste. 
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INTRODUCTION 
The HPLC method is an analytical method in which proving the 
separation-related impurities and its drug compound, and it helps to 
estimate the content of impurities and drugs to prove the quality of 
the drug substances [1-3]. In this study used UHPLC system and 
short column during development and the application of the UHPLC 
method is chromatographic method gained increasing importance 
because of their high selectivity, sensitivity and quick 
chromatographic separation method. In order to prove the quality of 
the drug substance being analyzed in sample solutions, it is 
necessary to measure the amount of impurities and drugs. By 
applying UHPLC concepts, it can reduce the run times of 
chromatographic methods and effluents and decrease the 
turnaround times [4-6]. Various UHPLC methods have been 
developed for the determination of related compounds and potency 
of the drug in pharmaceutical drug substances and formulations and 
many bioanalytical methods were developed to estimate the drug 
content in the pharmacy kinetic study and dietary samples [7-10]. 
Trichostatin A (TSA) is chemically known as, [R-(E,E)]-7-[4-
(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-Oxo-2,4-hepta-
dienamide (fig. 1). Trichostatin A is a hydroxamic acid. It has a role 
as a bacterial metabolite. It derives from a (R)-Trichostatic acid. TSA 
serves as an antifungal antibiotic and selectively inhibits the class I 
and II mammalian histone deacetylase (HDAC) families of enzymes, 
but not class III HDACs (i.e., sirtuins) [11, 12]. It is a member of a 
larger class of histone deacetylase inhibitors (HDIs or HDACIs) that 
have a broad spectrum of epigenetic activities. Thus, TSA has some 
potential as an anti-cancer drug [13, 14]. 
  
 
Fig. 1: Chemical structure of trichostatin A (TSA) 
 
TSA concentration was determined by high-performance liquid 
chromatography (HPLC)-UV assay (high dose) or by HPLC-multiple 
reaction monitoring assay (low dose) in plasma sample [15] and 
identification of the TSA by IEX-HPLC [16] and reported on stress 
studies of HDAC family compound YK-1101by HPLC–UV and HPLC–
TOF/MS methods [17] and also the majority of the reports were 
published on drug activity and metabolism [18-20]. 
Screening the literature, no related substances and assay method 
has been reported for the determination of TSA in pharmaceutical 
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samples. In the current study, a simple, rapid and reliable linear-
gradient UHPLC method is developed for the estimation of related 
substances and assay of TSA in pharmaceutical samples. The 
recommended method is validated according to ICH guidelines [21, 
22] and obtained results were meeting the desired criteria [23, 24] 
and established standard error. 
MATERIALS AND METHODS 
Apparatus 
The ultra-high performance liquid chromatographic method 
(UHPLC) system was used model of Agilent 1260 Infinity series with 
a diode array detector (quaternary pump: G1311B, column 
thermostat: G1316B, Autosampler with cooler: G1329B and G1330B 
and detector: G4212B) for method development and validation, the 
chromatographic data was recorded, peak purity of the TSA was 
tested by using Chemstation DAD software (Agilent Technologies, 
Clara, US). A column Poroshell SB C18 50×4.6 mm; 2.7 µm RRLC 
column manufactured by Agilent (Agilent Technologies, Clara, US) 
was procured from LCGC India.  
Materials 
Working standard of TSA procured from Merck, India and Active 
Pharma Ingredient (API) samples and related impurities (fig. 2) 
were taken from ecologic Research laboratory (Hyderabad, India), 
HPLC gradient grade acetonitrile, orthophosphoric acid, formic acid 
was used of HPLC grade manufactured by E. Merck was procured 
from a commercial source. HPLC grade water was obtained by a 
Millipore water purification system. 
 
 
Chemical structure of Impurity-1 
 
Chemical structure of Impurity-2 
 
Chemical structure of Impurity-3 
 
Chemical structure of Impurity-4 
Fig. 2: Chemical structure of related compounds of TSA 
 
Methods 
The UHPLC method [4] has developed for the chromatographic 
separation between TSA and its related compounds on Poroshell 
120 SB C18 (50×4.6) mm; 2.7 µm RRLC column using Agilent RRLC 
(UHPLC) system with linear gradient elution and the developed 
method was validated as per stated guidelines [21, 24] to meet the 
suitability of the method and method development efforts, the 
outcome of validation experimental results are described in results 
and discussion section. 
Preparation of standard solutions 
Standard solution 
TSA standard solution (500.65 µg/ml) was prepared by accurately 
transferring 50.065 mg into a 100 ml volumetric flask. The 
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compound was dissolved and diluted to the mark with diluent. The 
same solution was used for the assay determination. 
Impurities stock solutions 
TSA and related compound 5.03 µg/ml of TSA, 5.02 µg/ml of 
impurity-1, 5.12 µg/ml of impurity-2, 5.07 µg/ml of impurity-3 and 
5.17 µg/ml of impurity-4 stock solutions were prepared for the 
estimation of the related compound. 
Pharma samples for assay 
Sample solution (500.55 µg/ml) was prepared by accurately 
transferring the 50.055 mg into 100 ml volumetric flask and 
dissolved, diluted to the mark with diluent. This solution used for 
assay determination and related substances determination. 
RESULTS AND DISCUSSION 
Method development 
The main objective of the method is to develop a rapid and single 
chromatographic method for the estimation of assay and its related 
compounds of TSA from pharmaceutical research lab samples. As 
TSA and related impurities are contained N-hydroxy, amide and acid 
functional groups and the compounds are would be in neutral and 
acidic nature; therefore, the development trials were attempted 
under acidic conditions by taking mobile phase with formic acid, 
Trifluoroacetic acid and orthophosphoric acid on three different C18 
columns. At these chromatographic conditions, Waters X-terra MS 
C18, X-Bridge C18 column resolution between TSA and impurity-3 is 
co-eluted both pairs, whereas Poroshell SB C18 column good 
resolution was observed under Trifluoroacetic acid and Formic acid 
conditions, but baseline noise is more, and it can’t be attained 
sensitivity for the related compounds. Therefore, the ortho-
phosphoric acid mobile phase is chosen for the method optimization 
on the same column. 
Optimized chromatographic conditions 
The chromatographic separation was achieved on Poroshell SBC18 
UHPLC/RRLC column (50×4.6 mm; 2.7 µm) using mobile phase A as 
0.1% v/v orthophosphoric acid and mobile phase B as acetonitrile 
with a linear gradient program: time (min)/% B is 0/10, 7/65, 8/10, 
and 12/40 at a flow rate of 0.6 ml/min and the column temperature 
was maintained at 25 °C using 5.0 µl injection volume. Related 
impurities and TSA were monitored at 272 nm UV detection and the 
diluent solution was prepared as water, acetonitrile and formic acid 
ratio 65:35:0.1 for standard and sample solution preparations. 
Method validation 
Specificity/selectivity 
Specificity is to the ability to measure accurately and specifically the 
analyte of interest in the presence of other components that may be 
expected to be present in the sample matrix [21-25]. Specificity of 
the method was evaluated by injecting the blank, individual-related 
compounds and sample solution prepared by spiking related 
compounds of TSA at 0.1% level of test concentration used as 
system suitability check to verify the co-elution between peaks. The 
outcome of the specificity and system suitability test revealing that 
there was no interference from the blank peaks eluted at related 
compounds and TSA. The peak purity data shows the peaks are 
homogeneous and there was no co-eluting peak at the retention time 
of TSA peak and related compound peaks. The system suitability test 
results are given in table 1 and 2 and typical blank and system 
suitability (specificity) chromatograms are given in fig. 3 and 4, 
respectively.
 
Table 1: System suitability test (SST-1) results for related substances method 
Name Retention time (tR) in min USP resolution (Rs) USP theoretical plates (N) USP tailing factor (T) 
Impurity-1 5.260  39401 1.18 
Impurity-2 6.22 8.63 45619 1.90 
Trichostatin A (TSA) 6.97 6.36 53673 1.62 
Impurity-3 7.44 3.98 68598 1.11 
Impurity-4 8.35 7.42 65102 1.87 
n=1 injection 
 
Table 2: System suitability test (SST-2 and 3) results 
 System suitability test (SST-2)  name precision (n=6) results for related 
substances method 
System suitability test (SST-2) precision (n=6) results for 
the assay method 
Injection Area of TSA (0.5µg/ml) Area of TSA (500 µg/ml) 
Injection-1 10392 6882925 
Injection-2 11393 6943811 
Injection-3 10894 6970781 
Injection-4 11147 6933587 
Injection-5 10512 6920611 
Injection-6 10987 6896385 
mean±SD 10887.5±379.3 6924683.3±32035.2 




Fig. 3: A typical blank chromatogram 
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Fig. 4: A system suitability chromatogram 
 
Precision 
Precision of an analytical procedure is determined by assaying a 
sufficient number of aliquots of a homogeneous sample to be able to 
calculate statistically valid estimates of standard deviation or 
relative standard deviation [21]. For related compound method, six 
solutions containing TSA (500 µg/ml) were spiked with related 
compounds solutions 0.5 µg/ml (a 0.10% of TSA concentration). 
Chromatography was performed and value of %RSD was calculated 
considering peak area for TSA and each related compound. Similarly, 
intermediate precision of the method was also evaluated by another 
analyst, on a different day in the same laboratory. 
For assay method, six individual sample solutions were prepared TSA 
(500 µg/ml) and calculated assay of the compound against standard 
solution and also checked %RSD for assay values for six determinations. 
Similarly, intermediate precision of the method was also evaluated by 
another analyst, on a different day in the same laboratory. 
The outcome from the precision is showing for assay method is 
below 0.6% and related substances method is below 1.0% and as 
per FDA guideline stated that precision of method for assay should 
be less than 2% and the results are meeting the criteria [24] also 
calculated 95% confidence level and mean±standard error and the 
observed results are given in below table 2. 
 
Table 2: Precision results 
 Analyte/impurity TSA Impurity-1 Impurity-2 Impurity-3 Impurity-4 
Mean 99.0 0.24 0.28 0.25 0.20 
STDEV (σ) 0.51 0.02 0.01 0.00 0.01 
%RSD 0.52 6.36 1.99 1.62 4.29 
CI at 95% 99.0±0.408 0.24±0.016 0.28±0.004 0.25±0.003 0.20±0.007 
mean±SE 99.0±0.208 0.24±0.008 0.28±0.002 0.25±0.002 0.20±0.003 
#n=6 six determinations,0.15% level impurities with respect to analyte concentration (500 µg/ml), 100% level at assay conc.500 µg/ml of TSA, CI-
Confidence interval, SE–standard error 
 
Limit of detection and limit of quantitation 
Limit of detection (LOD) of an individual procedure is the lowest 
amount of analyte in a sample that can be detected but not necessarily 
quantitated as an exact value. In analytical procedures that exhibit 
baseline noise, the LOD can be based on a signal-to-noise (S/N) ratio 
(3:1), which is usually expressed as the concentration of an analyte in 
the sample. The signal-to-noise ratio is determined by: s = H/h Where 
H = height of the peak corresponding to the component. h = absolute 
value of the largest noise fluctuation from the baseline of the 
chromatogram of a blank solution. The limit of Quantitation (LOQ) or 
Quantitation limit of an individual analytical procedure is the lowest 
amount of analyte in a sample that can be quantitatively determined 
with suitable precision and accuracy. For analytical procedures such 
as HPLC that exhibit baseline noise, the LOQ is generally estimated 
from a determination of S/N ratio (10:1) and is usually confirmed by 
injecting standards which give this S/N ratio and have an acceptable 
percent relative standard deviation as well [24]. 
The proposed related substances method was checked for the 
method sensitivity for all related compounds and analyte, which 
shows excellent sensitivity and meeting to reporting threshold 
requirement (i.e., ≤ 0.05% level) [22]. LOQ precision and accuracy 
also executed and precision at LOQ level is shows<10% RSD and it is 
meeting to the acceptance criteria [23] and accuracy at LOQ level is 
described at accuracy parameter. The details of LOD, LOQ is given in 
table 3 and representative LOD and LOQ chromatograms are in fig. 5 
and 6. 
 
Table 3: LOD and LOQ for related substances method 
Parameter Impurity-1 Impurity-2 Impurity-3 Impurity-4 TSA 
LOD conc. (µg/ml) 0.075 0.077 0.076 0.077 0.075 
LOQ conc. (µg/ml) 0.251 0.256 0.254 0.258 0.252 
LOQ precision (%RSD for n=6) 5.4 6.1 5.7 7.9 3.9 
 
 
Fig. 5: Typical LOD chromatogram 
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Fig. 6: Typical LOQ chromatogram 
 
Linearity 
The linearity of an analytical procedure is its ability (within a given 
range) to obtain test results, which are directly proportional to the 
concentration of an analyte in the sample. For the establishment of 
linearity, a minimum of five concentrations are recommended by 
ICH guidelines [21]. 
For the related compound determination method, linearity was 
checked for related compounds and TSA at lower concentration 
levels 0.05% to 0.25% (i.e., 0.25 µg/ml to 1.25 µg/ml). The 
responses were measured as peak areas and plotted against 
concentration. The similar experiment was performed for assay 
method linearity by preparing the standard concentrations 80% to 
120% at assay concentration level (i.e., 400 µg/ml to 600 µg/ml). 
The calibration curve was drawn by plotting each impurity peak 
area versus its corresponding concentration. The correlation 
coefficient, slope, y-intercept, slope±SE calculated for each impurity 
and TSA were determined. Results are given in below table 4 and 5; 
linearity plots are given in fig. 7. 
The outcome for the related substances method data shows, the 
correlation and regression co-efficient values are greater than 0.995 
and these are well within the acceptable criteria [23, 24] and the 
standard error shows within 3% of slope value. For the assay 
method obtained data shows, correlation and regression co-efficient 
values are greater than 0.995, which is well with acceptance criteria 
and standard error shows with 0.15% of slope value. It reveals that 
both proposed methods are linear. 
 
Table 4: Linearity data of related substances method 












0.251 5091 0.256 4183 0.254 3466 0.258 4859 0.252 5170 
0.251 5498 0.256 4095 0.254 3612 0.258 4951 0.252 5287 
0.502 9373 0.512 8269 0.507 8415 0.515 11429 0.503 11005 
0.502 9879 0.512 9006 0.507 8697 0.515 10931 0.503 11393 
0.753 15431 0.768 13197 0.761 13478 0.753 15987 0.755 16582 
0.753 15065 0.768 12897 0.761 12745 0.753 16238 0.755 16931 
1.004 20005 1.024 16785 1.014 17102 1.030 21287 1.006 21412 
1.004 19875 1.024 16982 1.014 16997 1.030 21299 1.006 21785 
1.255 24333 1.280 20302 1.268 22104 1.288 27412 1.258 26311 













































n=2 injections at each level 
 
Table 5: Linearity data of assay method 
TSA 











Correlation (r) 0.9996 
Regression (r2) 0.9992 
Slope (m) 13838 
y-interccept (c) -37144 
Slope±SE 13838±19 
n=2 injections at each level 
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Fig. 7: Linearity plots of related substances method and assay method 
 
Accuracy 
Accuracy is the agreement between the test results obtained by the 
proposed method and the true value. It expresses the correctness of 
the method. It is expressed as a percentage by the assay of a known 
amount of substance. Accuracy also evaluated by recovery studies, in 
which a known amount of drug is added to previously analyzed 
pharmaceutical preparation of the drug and tested for the recovery 
of the added drug [23-27].  
The absolute error is a measure of the accuracy of the measurement; 
it is then calculated as given in Equation-1 
Absolute error = Mean error ×
True value − Measured value
True value
× 100 Equation − 1 
The accuracy of the assay method was evaluated in triplicate (n=3) 
at the concentration levels of TSA 400, 500 and 600 µg/ml (80%, 
100% and 120%) and the % recovery was calculated at each level 
and the recoveries were observed between 99.5% to 100.3%. These 
are well within the acceptance criterion for assay method i.e., 98.0 to 
102.0% [24] and which indicated that the proposed assay method is 
accurate. Results are given in table 6 and 7. 
 
Table 6: Accuracy results of an assay method 
Name % Level Amount added (µg/ml) Amount found (µg/ml) % Recovery 
TSA# 80 400.26 401.53 100.3 
100 500.65 497.83 99.4 
120 600.79 602.43 100.3 
Mean    100.0 
Std dev (σ)    0.50 
mean±SE    100.0±0.28 
% RSD    0.50 
#Assay concentration level recovery, n=3 determination at each level 
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Similarly, accuracy of the related substances method evaluated in 
triplicate (n=3) at the concentration levels of each related compound 
0.05%, 0.15% and 0.25% level and the % recovery was calculated 
for each related compound and the recoveries were found between 
91.5% to 98.5% which are well between acceptance criteria i.e., 80.0 
to 120.0%. The proposed related substances method is accurate. 
 
Table 7: Accuracy results of related substances method 
Name % Level Amount added (µg/ml) Amount found (µg/ml) % Recovery 
Impurity-1 LOQ 0.251 0.241 96.02 
0.15% 0.753 0.695 92.30 
0.25% 1.255 1.201 95.70 
Mean    94.67 
Std dev (σ)    2.06 
mean±SE    94.67±1.19 
%RSD    2.2 
Impurity-2 LOQ 0.256 0.247 96.48 
0.15% 0.768 0.714 92.97 
0.25% 1.280 1.214 94.84 
Mean    94.77 
Std dev (σ)    1.76 
mean±SE    94.77±1.02 
%RSD    1.9 
Impurity-3 LOQ 0.254 0.245 96.46 
0.15% 0.761 0.689 90.54 
0.25% 1.268 1.223 96.45 
Mean    94.48 
Std dev (σ)    3.42 
mean±SE    94.48±1.97 
%RSD    3.6 
Impurity-4 LOQ 0.258 0.241 93.41 
0.15% 0.753 0.699 92.83 
0.25% 1.288 1.238 96.12 
Mean    94.12 
Std dev (σ)    1.76 
mean±SE    94.12±1.01 
%RSD    1.9 
n=3 determinations at each level 
 
Stability of the solution 
A sample solution of assay method and related substance method 
was checked at different time intervals up to 48 h by keeping 
solution at room temperature and checked cumulative %RSD for the 
peak area of TSA and its related compounds. The %RSD of TSA and 
its related compound peak areas were found be less than 1% and 
8%, respectively. The stability of TSA sample solution in both 
proposed methods is stable up to 48 h. 
CONCLUSION 
The proposed linear-gradient UHPLC method is simple, rapid and 
selective and it was satisfying to all verified validation parameters, it 
indicates that the method is specific, precise, linear and accurate. In this 
method, TSA and its related compounds were eluted within 12 min run 
time of chromatographic elution and it shows very excellent turnaround 
time (TAT) outcome of the analysis. The developed method shows eco-
friendly when compared to regular conventional HPLC methods in terms 
of effluent load, analysis cost, energy cost. Therefore, the developed 
method is more suitable for the quantification of TSA and its related 
compounds in pharmaceutical samples; hence the proposed method is 
recommended to use research and pilot-scale laboratories. 
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